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INTRODUCTION
Hereditary angioedema (HAE) is a rare autosomal dominant 
disorder characterized by recurrent attacks of non-pitting sub-
mucosal and/or subcutaneous edema that usually involves the 
skin, gastrointestinal tract, and upper airways.1 An attack can 
persist for some time or improve spontaneously.2 In some cas-
es, however, laryngeal edema may lead to asphyxiation and 
death if it is not properly managed.3 
HAE is a disease of congenital deficiency or functional defect 
of the C1 esterase inhibitor (C1-INH) expressing gene SERP-
ING1.1 It is classified into 3 phenotypes: HAE type I which fea-
tures low C1-INH level and activity; HAE type II which features 
normal or high C1-INH level, but low activity; and type III 
which is a newly described, estrogen-dependent, inherited 
form that features normal protein and activity levels.4 Types I 
and II are consequent to mutations in SERPING1, whereas mis-
sense mutations in the gene encoding human coagulation fac-
tor XII have been reported in Type III cases.5
Although some cases of adult and pediatric HAE with low C1-
INH levels have been reported in Korea,6-8 a case involving both 
a high C1-INH level and decreased C1-INH function has not 
yet been described. Herein, we describe the case of a 24-year-
old woman with SERPING1-mutated HAE that was character-
ized by a high level, but diminished activity of serum C1-INH. 
 
CASE REPORT
A 24-year-old woman was referred to our Allergy Asthma 
Center with a history suggestive of HAE. Approximately 2 years 
earlier, she had experienced migrating soft tissue swelling in 
both hands, thighs, and feet twice monthly. She had also visited 
a private clinic for recurrent abdominal pain without altered 
bowel habits. Although medications were prescribed (raniti-
dine, rebamipide, and loperamide), most of her episodic symp-
toms disappeared without intervention. One year after symp-
tom onset, she began working as a kindergarten teacher and 
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experienced considerable stress; her symptoms subsequently 
began to emerge at approximately 1-week intervals. Shortly be-
fore visiting our clinic, she developed abdominal pain, edema 
of both hands, and dyspnea due to upper airway swelling. Her 
symptoms did not improve with antihistamine medication, but 
they subsequently spontaneously resolved. She had experi-
enced these episodes only in the last 2 years, and she had had 
no prior attacks. Furthermore, she had no other medical histo-
ry, and neither parent had a history of angioedema.
Her initial physical examination revealed the following. Her 
vital signs were non-significant. Both hands and forearms 
swelled, but did not show overlying erythema, urticaria, pitting, 
redness, or tenderness (Figure). The swelling persisted >24 
hours and subsided without specific treatment. Laboratory 
findings included leukocyte, eosinophil, and platelet counts of 
6,300/mm3, 120/µL, and 381,000/mm3, respectively; a hemo-
globin level of 13.5 g/dL; and serum total IgE level of 12.7 kUA/
L. Serum cryoglobulin, rheumatoid factor, or anti-CCP was not 
detected. An antinuclear-antibody test was positive (1:80, 
speckled). However, further autoantibody evaluation yielded 
negative anti-Smith Ab, anti-SSA/Ro, anti-SSB/La, anti-cardio-
lipin IgG and IgM, anti-β2 glycoprotein IgG and IgM, and anti-
dsDNA IgG. Her C4 (3.40 mg/dL, normal: 10.0-40.0 mg/dL) and 
CH50 levels (4.9 U/mL; normal: 36.2-69.6 U/mL) were low, and 
her C3 (143 mg/dL; normal: 77.0-195.0 mg/dL) and circulating 
immune complex (<1.5 μg/mL; normal: 0.0-3.0 μg/mL) levels 
were within normal ranges. However, her C1-INH level was 
high, at 81.90 mg/dL (normal: 21.0-39.0 mg/dL). A C1-INH 
functional assay and genetic testing for the presence of muta-
tion in SERPING1 revealed a decreased functional activity level 
of C1-INH (less than 25%, normal: 70%-130%) and a missense 
mutation in exon 8 of SERPING1. This heterozygous 1396 C→T 
mutation caused an Arg→Cys substitution in 466th amino acid 
of C1-INH. 
The patient took a leave of absence from work after develop-
ing laryngeal edema. She was averse to danazol treatment be-
cause of its side effects, such as increased sebum production, 
rapid weight gain, virilization, and hyposexuality. Hence, we 
prescribed tranexamic acid for prophylaxis. Eight weeks later, 
she continued to experience HAE-related symptoms, though 
both the frequency and severity of attacks had lessened. 
DISCUSSION
The C1-INH deficiency that is characteristic of HAE results 
from a mutation in SERPING1 on the eleventh chromosome 
(11q11–q13.1).9 C1-INH is a protease inhibitor belonging to the 
serpin superfamily.10 The main role of C1-INH is inhibition of 
the complement system, thus avoiding spontaneous activa-
tion.11 Subcutaneous and submucosal non-pitting edema with-
out pruritus is characteristic of HAE. These self-limiting lesions 
are thought to be triggered by environmental factors and patho-
physiologic mechanisms.9 They resolve spontaneously within 
several days and recur.11 Edema results from a transient in-
crease in capillary endothelial permeability, consequent to ex-
cessive bradykinin release.11,12 
The estimated general prevalence of HAE is approximately 1 
case per 30,000-50,000 persons.13 However, the prevalence of 
HAE in Korea remains unknown. According to a study of physi-
cians who were members of The Korean Academy of Asthma, 
Allergy and Clinical Immunology, only 13 physicians in Korea 
reported confirmed HAE cases among their patients, suggest-
ing underdiagnosis.14 Furthermore, to date, only cases of type I 
HAE have been reported in Korea.14 
Mutations that affect the reactive-center arginyl residue on 
exon 8 (Arg444Cys) are well known in patients with HAE.15 Al-
though most HAE patients have a classic family history, approx-
imately 25% (including our patient) have none, suggesting the 
presence of de novo mutations of SERPING1.1 However, the de-
tection of an autosomal dominant mutation in our patient indi-
cated that genetic counseling was needed for her family, to as-
sess risks and explore potential morbidities. 
Two types of treatment are available for HAE: acute symptom-
atic (i.e., for laryngeal edema) and prophylactic treatments.4 
Figure. The left hand of the patient. Swelling of the patient’s forearm was evident on the day following an attack of angioedema (A). Her normal condition after 
treatment is shown for comparison (B).
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Acute treatment consists of the administration of C1-INH con-
centrates, kallikrein inhibitors, or fresh frozen plasma to Type I 
and II HAE patients.16 However, patients with Type III HAE do 
not benefit from C1-INH infusion.16 Although plasma-derived 
C1-INH was previously only available from the Korea Orphan 
Drug Center, it has been supplied by pharmaceutical companies 
since 2013. Patients with frequent episodes and those at high 
risk of developing laryngeal edema require long-term prophy-
laxis with danazol or antifibrinolytic agents.17 We prescribed a 
prophylactic drug for our patient, to treat the gastrointestinal 
and respiratory symptoms associated with monthly recurrences.
In conclusion, we reported a case involving a 24-year-old 
woman with angioedema that was typical of HAE, a significant-
ly high C1-INH level, and low C1-INH activity. To our knowl-
edge, this is the first case of type 2 HAE in Korea. 
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